$キオラ・ファーマシューティカルズ(KPRX.US)$Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study Thu, Apr 11, 2024 Encinitas, California--(Newsfile Corp. - April 11, 2024) -Kiora Pharmaceuticals, Inc.(NASDAQ: KPRX) has received grant funding from the Choroideremia Research Foundation (CRF) in support of validating functional vision assessments for pat...
$キオラ・ファーマシューティカルズ(KPRX.US)$Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye newsfile· 6 mins ago
$キオラ・ファーマシューティカルズ(KPRX.US)$NASDAQ: KPRX) entered into an agreement with Théa Open Innovation SAS (TOI) concerning the KIO-301 molecular photoswitch product. According to the agreement, Kiora Pharmaceuticals has granted TOI an exclusive, sublicensable license to pursue development, manufacturing, commercialization, and regulatory approvals for the product globally, excluding specific Asian countries. The focus of the product’s use will be on treating retinitis ...
キオラ・ファーマシューティカルズに関するコメント
Update
Thu, Apr 11, 2024
Encinitas, California--(Newsfile Corp. - April 11, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) has received grant funding from the Choroideremia Research Foundation (CRF) in support of validating functional vision assessments for pat...
Update
newsfile· 6 mins ago
For those that want a summary!
まだコメントはありません